Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices in Europe, the United States, the United Kingdom, and internationally.
+ 2 more risks
Reasonable growth potential and slightly overvalued.
Share Price & News
How has Consort Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CSRT's share price has been volatile over the past 3 months.
7 Day Return
GB Medical Equipment
1 Year Return
GB Medical Equipment
Return vs Industry: CSRT underperformed the UK Medical Equipment industry which returned 30.4% over the past year.
Return vs Market: CSRT exceeded the UK Market which returned 6.1% over the past year.
Price Volatility Vs. Market
How volatile is Consort Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall StIs Consort Medical plc's (LON:CSRT) High P/E Ratio A Problem For Investors?
1 year ago | Simply Wall StDo You Know About Consort Medical plc’s (LON:CSRT) ROCE?
1 year ago | Simply Wall StHow Much Money Does Consort Medical plc (LON:CSRT) Make?
Is Consort Medical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CSRT (£10.05) is trading below our estimate of fair value (£12.38)
Significantly Below Fair Value: CSRT is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: CSRT is poor value based on its PE Ratio (126.5x) compared to the Medical Equipment industry average (33.6x).
PE vs Market: CSRT is poor value based on its PE Ratio (126.5x) compared to the UK market (18.5x).
Price to Earnings Growth Ratio
PEG Ratio: CSRT is poor value based on its PEG Ratio (3.2x)
Price to Book Ratio
PB vs Industry: CSRT is good value based on its PB Ratio (2.2x) compared to the GB Medical Equipment industry average (3.3x).
How is Consort Medical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CSRT's forecast earnings growth (39.3% per year) is above the savings rate (0.5%).
Earnings vs Market: CSRT's earnings (39.3% per year) are forecast to grow faster than the UK market (12.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CSRT's revenue (3.6% per year) is forecast to grow faster than the UK market (3.5% per year).
High Growth Revenue: CSRT's revenue (3.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CSRT's Return on Equity is forecast to be low in 3 years time (14.6%).
How has Consort Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CSRT has a large one-off loss of £23.6M impacting its October 31 2019 financial results.
Growing Profit Margin: CSRT's current net profit margins (1.3%) are lower than last year (5.4%).
Past Earnings Growth Analysis
Earnings Trend: CSRT's earnings have grown by 2.7% per year over the past 5 years.
Accelerating Growth: CSRT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CSRT had negative earnings growth (-76.8%) over the past year, making it difficult to compare to the Medical Equipment industry average (-4.5%).
Return on Equity
High ROE: CSRT's Return on Equity (1.7%) is considered low.
How is Consort Medical's financial position?
Financial Position Analysis
Short Term Liabilities: CSRT's short term assets (£140.6M) exceed its short term liabilities (£76.9M).
Long Term Liabilities: CSRT's short term assets (£140.6M) do not cover its long term liabilities (£173.3M).
Debt to Equity History and Analysis
Debt Level: CSRT's debt to equity ratio (55.6%) is considered high.
Reducing Debt: CSRT's debt to equity ratio has increased from 1.3% to 55.6% over the past 5 years.
Debt Coverage: CSRT's debt is not well covered by operating cash flow (11.8%).
Interest Coverage: CSRT's interest payments on its debt are well covered by EBIT (8.8x coverage).
Inventory Level: CSRT has a high level of physical assets or inventory.
Debt Coverage by Assets: CSRT's debt is covered by short term assets (assets are 1.1x debt).
What is Consort Medical's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CSRT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CSRT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CSRT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CSRT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: CSRT is not paying a notable dividend for the UK market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CSRT's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Quick (53yo)
Mr. Mark Quick has been Chief Executive Officer at Consort Medical plc since February 2020. He serves as an Executive Vice President of Corporate Development at Recipharm AB and Recipharm AB (publ). Mr. Qu ...
|CFO & Executive Director||2.75yrs||UK£635.00k||0.024% £120.6k|
|Chief Executive Officer||no data||no data||no data|
|Vice President of Operations||1.08yrs||no data||no data|
|Group General Counsel & Company Secretary||1.5yrs||no data||no data|
|Director of Human Resources||11.5yrs||no data||no data|
|Group Financial Controller||no data||no data||no data|
|Business President of Bespak Drug Delivery Devices||2.08yrs||no data||0.051% £249.7k|
Experienced Management: CSRT's management team is considered experienced (2.1 years average tenure).
|CFO & Executive Director||2.75yrs||UK£635.00k||0.024% £120.6k|
|Senior Independent Director||8.42yrs||UK£66.16k||0.0033% £16.3k|
|Non-Executive Director||7.67yrs||UK£47.22k||0.0048% £23.7k|
|Non-Executive Director||7.67yrs||UK£50.13k||0.0020% £10.1k|
|Non Executive Director||5.58yrs||UK£44.51k||0.0032% £16.0k|
|Chairman||no data||no data||no data|
|Non-Executive Director||5yrs||UK£42.03k||0.0019% £9.5k|
Experienced Board: CSRT's board of directors are considered experienced (6.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CSRT insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Consort Medical plc's company bio, employee growth, exchange listings and data sources
- Name: Consort Medical plc
- Ticker: CSRT
- Exchange: LSE
- Founded: 1946
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: UK£493.441m
- Shares outstanding: 49.10m
- Website: https://www.consortmedical.com
Number of Employees
- Consort Medical plc
- Breakspear Park
- Suite B
- Hemel Hempstead
- HP2 4TZ
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CSRT||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||GBP||Jan 1992|
|8C7||BST (Boerse-Stuttgart)||Yes||Ordinary Shares||DE||EUR||Jan 1992|
|CSRTl||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||GBP||Jan 1992|
Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices in Europe, the United States, the United Kingdom, and internationally. It operates through two segments, Bespak and Aesica. The company provides various life improving treatments to patients worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products. It also develops, formulates, and manufactures active pharmaceutical ingredients, such as flurbiprofen, and finished dose drugs. Consort Medical plc was incorporated in 1946 and is based in Hemel Hempstead, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/17 20:39|
|End of Day Share Price||2020/02/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.